Authors:
Brada, M
Hoang-Xuan, K
Rampling, R
Dietrich, PY
Dirix, LY
Macdonald, D
Heimans, JJ
Zonnenberg, BA
Bravo-Marques, JM
Henriksson, R
Stupp, R
Yue, N
Bruner, J
Dugan, M
Rao, S
Zaknoen, S
Citation: M. Brada et al., Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse, ANN ONCOL, 12(2), 2001, pp. 259-266
Authors:
Rampling, R
Cruickshank, G
Papanastassiou, V
Nicoll, J
Hadley, D
Brennan, D
Petty, R
MacLean, A
Harland, J
McKie, E
Mabbs, R
Brown, M
Citation: R. Rampling et al., Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma, GENE THER, 7(10), 2000, pp. 859-866
Authors:
Yung, WKA
Albright, RE
Olson, J
Fredericks, R
Fink, K
Prados, MD
Brada, M
Spence, A
Hohl, RJ
Shapiro, W
Glantz, M
Greenberg, H
Selker, RG
Vick, NA
Rampling, R
Friedman, H
Phillips, P
Bruner, J
Yue, N
Osoba, D
Zaknoen, S
Levin, VA
Citation: Wka. Yung et al., A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, BR J CANC, 83(5), 2000, pp. 588-593
Authors:
Mairs, RJ
Wideman, CL
Angerson, WJ
Whateley, TL
Reza, MS
Reeves, JR
Robertson, LM
Neshasteh-Riz, A
Rampling, R
Owens, J
Allan, D
Graham, DI
Citation: Rj. Mairs et al., Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model, BR J CANC, 82(1), 2000, pp. 74-80